Nabriva gets a win, but investors are lukewarm


US approval for Nabriva Therapeutics' antibiotic lefamulin left investors unimpressed this morning, and failed repair the damage done by the receipt of a complete response letter back in April for another of the company's antibiotic projects, Contepo. But lefamulin, approved for community-acquired bacterial pneumonia, will at least bring in a steady stream of revenue: Nabriva has priced the IV form of lefamulin at $205 per day, and the oral version at $275 per day. To be branded Xenleta, the product is seen by the sellside as potentially a bigger product than Contepo, according to data compiled by EvaluatePharma. Shareholders are perhaps wary of a possible cash call that could now emerge – Nabriva recently said that it had funds to last until the second quarter of next year. On Friday the company revealed that Contepo would be resubmitted to the FDA by the end of this year, by which time the manufacturing issues at the contractor, which prompted the CRL, should have been addressed – meaning another revenue stream could soon be on the way.

Nabriva Therapeutics
  Annual sales WW ($m)
Product 2019e 2020e 2021e 2022e 2023e 2024e
Xenleta (lefamulin) 5 34 77 141 221 301
Contepo (fosfomycin) 1 5 13 30 49 70
Source: EvaluatePharma.

Share This Article